| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| bupivacaine hydrochloride | Injection, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 6/12/2024 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 6/12/2024 |
| finasteride | Tablet, film coated | 1 mg | Resolved | Available | Unexpected increase in consumer demand | 6/12/2024 |
| docetaxel | Injection, concentrated | 80 mg | Current | Limited Availability | Manufacturing | 6/12/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 8 mg | Current | Unavailable | Manufacturing | 6/12/2024 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 6/12/2024 |
| adenosine | Solution | 30 mg | Current | Limited Availability | Manufacturing | 6/12/2024 |
| lorazepam | Tablet | 2.5 mg | Anticipated | Available | Manufacturing | 6/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/12/2024 |
| olanzapine | Injection, powder for | 10 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 6/12/2024 |
| amlodipine besilate | Tablet, uncoated | 6.94 mg | Current | Limited Availability | Manufacturing | 5/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Discontinued | Unavailable | Manufacturing | 5/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Discontinued | Unavailable | Manufacturing | 5/12/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Resolved | Available | Manufacturing | 5/12/2024 |
| letrozole | Tablet, film coated | 2.5 mg | Resolved | Available | Manufacturing | 5/12/2024 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Current | Limited Availability | Manufacturing | 5/12/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Unavailable | Manufacturing | 5/12/2024 |
| gemfibrozil | Tablet, film coated | 600 mg | Current | Limited Availability | Manufacturing | 5/12/2024 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 5/12/2024 |
| nizatidine | Capsule | 150 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/12/2024 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 5/12/2024 |
| moclobemide | Tablet, film coated | 150 mg | Current | Limited Availability | Manufacturing | 5/12/2024 |
| testosterone enantate | Injection | 250 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 4/12/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Manufacturing | 4/12/2024 |
| sodium fluoride | Injection, concentrated | 1 mg/mL | Current | Limited Availability | Manufacturing | 4/12/2024 |
| fentanyl | Drug delivery system, transdermal | 2.1 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 4/12/2024 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Anticipated | Available | Manufacturing | 4/12/2024 |
| dopamine hydrochloride | Injection, concentrated | 40 mg/mL | Current | Limited Availability | Manufacturing | 4/12/2024 |
| hydrochlorothiazide~telmisartan | Tablet, film coated | 12.5 mg~80 mg | Resolved | Available | Manufacturing | 4/12/2024 |
| acarbose | Tablet | 100 mg | Current | Unavailable | Manufacturing | 4/12/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 4/12/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 4/12/2024 |
| lamotrigine | Tablet, chewable | 100 mg | Anticipated | Available | Unexpected increase in consumer demand | 4/12/2024 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Unexpected increase in consumer demand | 4/12/2024 |
| midazolam | Injection, solution | 1 mg/mL | Resolved | Available | Manufacturing | 4/12/2024 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Resolved | Available | Manufacturing | 4/12/2024 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Resolved | Available | Manufacturing | 3/12/2024 |
| topiramate | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 3/12/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| olanzapine pamoate monohydrate | Injection, powder for | 483 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Limited Availability | Manufacturing | 3/12/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/12/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/12/2024 |
| risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 33.75 mg~200 mg~125 mg | Anticipated | Available | Manufacturing | 3/12/2024 |
| midazolam | Injection, solution | 5 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| midazolam | Injection, solution | 5 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| desvenlafaxine | Tablet, modified release | 50 mg | Anticipated | Available | Manufacturing | 3/12/2024 |
| temozolomide | Capsule, hard | 20 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Manufacturing | 3/12/2024 |
| hydromorphone hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/12/2024 |
| tadalafil | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 3/12/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Anticipated | Available | Manufacturing | 3/12/2024 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| tadalafil | Tablet, film coated | 5 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2024 |
| tenofovir disoproxil fumarate | Tablet | 300 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| pregabalin | Capsule, hard | 75 mg | Anticipated | Available | Unexpected increase in consumer demand | 3/12/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 3/12/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/12/2024 |
| thiotepa | Injection, powder for | 15 mg | Resolved | Available | Unexpected increase in consumer demand | 3/12/2024 |
| lanreotide acetate | Injection, solution | 66.67 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 3/12/2024 |
| melatonin | Capsule, hard | 5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 3/12/2024 |
| dabigatran etexilate mesilate | Capsule | 86.475 mg | Resolved | Available | Manufacturing | 3/12/2024 |
| aciclovir | Injection, solution | 25 mg/mL | Current | Unavailable | Manufacturing | 3/12/2024 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Resolved | Available | Manufacturing | 3/12/2024 |
| quinapril hydrochloride~hydrochlorothiazide | Tablet, film coated | 10.832 mg~12.5 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| hydrochlorothiazide~quinapril hydrochloride | Tablet, film coated | 12.5 mg~21.664 mg | Current | Unavailable | Manufacturing | 3/12/2024 |
| esomeprazole sodium | Injection, powder for | 42.5 mg | Resolved | Available | Manufacturing | 3/12/2024 |
| anidulafungin | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| pentetic acid | Injection, powder for | 5 mg | Current | Emergency Supply Only | Manufacturing | 2/12/2024 |
| medronic acid | Injection, powder for | 10 mg | Current | Limited Availability | Manufacturing | 2/12/2024 |
| papaverine hydrochloride | Injection, solution | 12 mg/mL | Resolved | Available | Manufacturing | 2/12/2024 |
| tacrolimus monohydrate | Capsule, hard | 1.022 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 2/12/2024 |
| levetiracetam | Tablet, film coated | 500 mg | Anticipated | Available | Manufacturing | 2/12/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 2/12/2024 |
| diazepam | Tablet, uncoated | 2 mg | Current | Limited Availability | Manufacturing | 2/12/2024 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Anticipated | Available | Manufacturing | 2/12/2024 |
| sumatriptan succinate | Tablet, film coated | 69.99 mg | Resolved | Available | Unexpected increase in consumer demand | 2/12/2024 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet, film coated | 25 mg~40 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| fenofibrate | Tablet | 48 mg | Anticipated | Available | Manufacturing | 2/12/2024 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Manufacturing | 2/12/2024 |
| acamprosate calcium | Tablet, enteric coated | 333 mg | Anticipated | Available | Manufacturing | 2/12/2024 |
| dasatinib | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| dasatinib | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| dasatinib | Tablet, film coated | 70 mg | Resolved | Available | Commercial Changes / Commercial viability | 2/12/2024 |
| atomoxetine hydrochloride | Capsule, hard | 114 mg | Anticipated | Available | Manufacturing | 2/12/2024 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 2/12/2024 |
| lacosamide | Tablet, film coated | 50 mg | Current | Limited Availability | Manufacturing | 2/12/2024 |
| lacosamide | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| levetiracetam | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 2/12/2024 |
| pregabalin | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 2/12/2024 |
| fentanyl citrate | Injection, solution | 157 microgram | Current | Unavailable | Manufacturing | 2/12/2024 |
| erythromycin ethyl succinate | Oral Liquid, powder for | 468 mg | Resolved | Available | Unexpected increase in consumer demand | 2/12/2024 |
| clindamycin phosphate | Cream | 22.8 mg/g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 2/12/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Current | Limited Availability | Manufacturing | 2/12/2024 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 2/12/2024 |
2024年12月9日